Actinium Pharmaceuticals Inc (ATNM) Dividend History

$7.94 $-0.18

Dividend Score
Dividend Yield
0%

Annual Payment
$0

Payout Ratio
0%
Dividend Increases
0 yrs

Price Chart

Key Metrics

Sector Healthcare
Industry Biotechnology
Avg daily volume 517,702
Market cap 225,446,000
Beta 0.02
Trailing 12 Month EPS -1.93
Next Earnings Date
Ex-dividend date
P/E ratio 0

Company Description

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o

Dividend Payments

Forward Yield
0%
Forward Payment
$0

Trailing Yield
0%
Trailing Payment
$0

Last Increase
> 10 Years Ago
Last Cut
> 10 Years Ago

5 Year Average Yield
0%
Vs Current Yield
0%

5 Year Div Growth Rate
0%
Payment Frequency
-

Historical Dividend Payments